人脑工程迎重磅利好！概念股盘点来了

Core Viewpoint - The article highlights the strong performance of the brain-machine interface (BMI) sector, driven by favorable policy developments and market growth projections in China and globally [5]. Summary by Sections Market Performance - On August 8, the BMI sector showed significant gains, with companies like Botao Bio, Mylande, Meihao Medical, Lepu Medical, and Sanbo Brain Science experiencing notable increases in stock prices [5]. Policy Developments - A joint announcement by seven departments, including the Ministry of Industry and Information Technology, aims to promote innovation in the BMI industry. The goal is to achieve breakthroughs in key technologies by 2027 and establish a reliable industrial system by 2030, fostering 2-3 globally influential leading companies and a number of specialized small and medium enterprises [5]. Regional Support - Various provinces and cities, including Beijing, Shanghai, Nanjing, Sichuan, and Shandong, have introduced policies this year to support the development of the BMI industry [5]. Market Size Projections - According to CCID Consulting, the Chinese BMI market is projected to reach 3.203 billion yuan in 2024, representing a year-on-year growth of 18.8%. The market size is expected to grow to 3.83 billion yuan in 2025, 4.646 billion yuan in 2026, and 5.575 billion yuan in 2027 [5]. Global Market Outlook - McKinsey forecasts that the global market for medical applications of BMI could reach $40 billion by 2030 and $145 billion by 2040 [5]. Industry Trends - Open Source Securities notes that the BMI technology landscape is rich and undergoing rapid transformation, with advancements in upstream technologies leading to breakthroughs in downstream applications. Domestic BMI companies are expected to gradually achieve commercialization, resulting in rapid market expansion in the future [5].